SCHEMBL4288319

SCHEMBL4288319

Cc1ccc(C(N)=O)c(-c2ccnc3[nH]ncc23)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 4/20 0.43
SIRT3 Q9NTG7 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
BRD4 O60885 1/20 0.39
PKMYT1 Q99640 1/20 0.38
NUDT1 P36639 2/20 0.38
PRKCQ Q04759 3/20 0.38
PAK1 Q13153 2/20 0.38
TLR7 Q9NYK1 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
CSNK1D P48730 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38
JAK3 P52333 1/20 0.38
TEC P42680 2/20 0.38
BMX P51813 2/20 0.38
LCK P06239 1/20 0.37
LYN P07948 1/20 0.37
HCK P08631 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288326 0.92 BTK (0.44) BTKSIRT3TDP1BRD4PKMYT1
SCHEMBL27399023 0.76 BTK (0.39) BTKBRD4NUDT1PRKCQTLR7
SCHEMBL4768901 0.75 NUDT1 (0.65) BTKBRD4NUDT1PRKCQPAK1
SCHEMBL1694892 0.74 RET (0.46) BTKSIRT3TDP1BRD4NUDT1
SCHEMBL29499046 0.74 RET (0.46) BTKSIRT3TDP1BRD4NUDT1
SCHEMBL4770932 0.72 NUDT1 (0.41) BTKNUDT1PRKCQMAPK14TNK2
SCHEMBL27399123 0.70 BTK (0.39) BTKBRD4NUDT1PRKCQTLR7
SCHEMBL4813157 0.69 JAK3 (0.51) BTKJAK3TECSRCTNK2
SCHEMBL16382710 0.68 BTK (0.53) BTKSIRT3TDP1PKMYT1JAK3
SCHEMBL4665514 0.68 PTGDR2 (0.42) BTKSIRT3TDP1PKMYT1NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8080546-B2 Pyrazolo-pyridinone derivatives and methods of use AMGEN INC. (US) 2011-12-20 US disclosed
US-20090137582-A1 Pyrazolo-pyridinone derivatives and methods of use AMGEN INC. (US) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137582-A1 Pyrazolo-pyridinone derivatives and methods of use IL1B, IL1R1, IL1A BTK 1160/4885SIRT3 757/4885TDP1 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.